Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.
2.

A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.

Maier LS.

J Cardiovasc Pharmacol. 2009 Oct;54(4):279-86. doi: 10.1097/FJC.0b013e3181a1b9e7. Review.

3.

Late sodium current inhibition as a new cardioprotective approach.

Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA.

J Mol Cell Cardiol. 2008 Jun;44(6):954-67. doi: 10.1016/j.yjmcc.2008.03.019. Epub 2008 Apr 8. Review.

PMID:
18462746
4.

Ranolazine: an antianginal drug with antiarrhythmic properties.

Tamargo J, Caballero R, Delp├│n E.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27. doi: 10.1586/erc.11.91. Review.

PMID:
21809962
5.

Ranolazine: clinical applications and therapeutic basis.

Hawwa N, Menon V.

Am J Cardiovasc Drugs. 2013 Feb;13(1):5-16. doi: 10.1007/s40256-012-0003-2. Review.

PMID:
23335347
6.

Ranolazine: effects on ischemic heart.

Rognoni A, Barbieri L, Cavallino C, Bacchini S, Veia A, Degiovanni A, Rametta F, Nardi F, Lazzero M, Lupi A, Bongo AS.

Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):197-203. Review.

PMID:
23961914
7.
8.

Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.

Doshi D, Morrow JP.

Rev Cardiovasc Med. 2009;10 Suppl 1:S46-52. Review.

PMID:
19898288
9.

Update on ranolazine in the management of angina.

Codolosa JN, Acharjee S, Figueredo VM.

Vasc Health Risk Manag. 2014 Jun 24;10:353-62. doi: 10.2147/VHRM.S40477. eCollection 2014. Review.

10.

The antiarrhythmic effects of ranolazine.

Foster NJ, Haines DE.

Rev Cardiovasc Med. 2009;10 Suppl 1:S38-45. Review.

PMID:
19898287
11.

A focus on antiarrhythmic properties of ranolazine.

Vizzardi E, D'Aloia A, Quinzani F, Bonadei I, Rovetta R, Bontempi L, Curnis A, Dei Cas L.

J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):353-6. doi: 10.1177/1074248412442000. Epub 2012 Apr 6. Review.

PMID:
22492919
12.

Ranolazine: a new approach to treating an old problem.

Reddy BM, Weintraub HS, Schwartzbard AZ.

Tex Heart Inst J. 2010;37(6):641-7. Review.

13.

The role of late I Na in development of cardiac arrhythmias.

Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L.

Handb Exp Pharmacol. 2014;221:137-68. doi: 10.1007/978-3-642-41588-3_7. Review.

14.

Ranolazine in the management of chronic stable angina.

Zerumsky K, McBride BF.

Am J Health Syst Pharm. 2006 Dec 1;63(23):2331-8. Review.

PMID:
17106005
15.

Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.

Stone PH.

Cardiol Clin. 2008 Nov;26(4):603-14. doi: 10.1016/j.ccl.2008.06.002. Review.

PMID:
18929234
16.

Ranolazine in Cardiac Arrhythmia.

Saad M, Mahmoud A, Elgendy IY, Richard Conti C.

Clin Cardiol. 2016 Mar;39(3):170-8. doi: 10.1002/clc.22476. Epub 2015 Oct 13. Review.

17.

Ranolazine for chronic stable angina.

Nash DT, Nash SD.

Lancet. 2008 Oct 11;372(9646):1335-41. doi: 10.1016/S0140-6736(08)61554-8. Review. Erratum in: Lancet. 2009 Feb 28;373(9665):722.

PMID:
18929905
18.

New treatment options for late Na current, arrhythmias, and diastolic dysfunction.

Maier LS.

Curr Heart Fail Rep. 2012 Sep;9(3):183-91. doi: 10.1007/s11897-012-0099-3. Review.

19.

Ranolazine for the management of coronary artery disease.

Cheng JW.

Clin Ther. 2006 Dec;28(12):1996-2007. Review.

PMID:
17296457
20.

Mechanism of action of the new anti-ischemia drug ranolazine.

Hasenfuss G, Maier LS.

Clin Res Cardiol. 2008 Apr;97(4):222-6. Epub 2007 Nov 28. Review.

Supplemental Content

Support Center